Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide.

Antimicrobial agents and chemotherapy - 1 Sept 2010

Depatureaux Agnès, Charpentier Charlotte, Collin Gilles, Leoz Marie, Descamps Diane, Vessière Aurélia, Damond Florence, Rousset Dominique, Brun-Vézinet Françoise, Plantier Jean-Christophe

Abstract excerpt

We assessed the natural genotypic and phenotypic susceptibilities to enfuvirtide of 171 HIV group O (HIV-O) samples and 29 strains, respectively. The N42D resistance-associated mutation in the gp41 region was detected in 98% of cases. The phenotypic assay showed a wide range of baseline susceptibilities, with 50% inhibitory concentrations (IC(50)s) from 4 to 5,000 nM, a range similar to that reported for HIV-1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Enfuvirtide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Envelope Protein gp41

Share to HIV Infections

Share to Inhibitory Concentration 50

Share to Molecular Sequence Data

Share to Peptide Fragments

Source

Open in PubMed Open full text

Identifiers

PMID: 20547806
DOI: 10.1128/AAC.00100-10
PMCID: PMC2935004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide.PMID 20547806Read ↗

Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates.Semantic proximity Read ↗

HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors.Semantic proximity Read ↗

Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2.Semantic proximity Read ↗

Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analysesSemantic proximity Read ↗

HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs.Semantic proximity Read ↗

HIV-1 gp41 genetic diversity and enfuvirtide resistance-associated mutations among enfuvirtide-naïve patients in southern China.Semantic proximity Read ↗

Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations.Semantic proximity Read ↗

Genotypic analysis of the gp41 HR1 region from HIV-1 isolates from enfuvirtide-treated and untreated patients.Semantic proximity Read ↗

HIV-1 Group O Resistance Against Integrase Inhibitors.Semantic proximity Read ↗

Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide.Semantic proximity Read ↗

HIV type-1 group O infection in Gabon: low prevalence rate but circulation of genetically diverse and drug-resistant HIV type-1 group O strains.Semantic proximity Read ↗

Variants with different mutation patterns persist in the quasispecies of enfuvirtide-resistant HIV-1 population during and after treatment in vivo.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.